Soligenix

Banking

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

February 14, 2023
Photo of Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

[ad_1] Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb.…

Read More »
Banking

Soligenix Announces Reverse Stock Split

February 9, 2023
Photo of Soligenix Announces Reverse Stock Split

[ad_1] Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J., Feb. 9, 2023 /PRNewswire/ — Soligenix,…

Read More »
Back to top button
Close